Nov 7 Statement | UMR Congratulates Dr. Monica Bertagnolli on her Confirmation as the next NIH Director
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
2023 Rural State Analysis | UMR's Newest Report Reveals the Exponential Impact of NIH Research Funding in Rural States
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Antibody Infusion Treatment Offers Peace of Mind for People at High Risk for Severe Illness From COVID-19

Monoclonal antibody infusion is shown to significantly reduce the risk of hospitalization or death in people age 65 or older, and those with certain chronic medical conditions, such as diabetes, heart disease, or obesity. Children ages 12 and over who have serious medical conditions may also benefit from the treatment.

“Nationally, individuals with certain risk factors who develop COVID-19 have a 15 percent chance of being hospitalized,” said Brian J. Young, MD, of Penn Medicine Lancaster General Health Physicians Family Medicine Twin Rose. “The infusion treatment reduces that risk to less than 5 percent.”